THC · Tenet Healthcare Corporation New · Stock research

(All figures below are public: company releases, Form 4 filings, sell-side actions and exchange prices. Nothing here is a recommendation.)

THC — Tenet Healthcare Corporation

Current Thesis

The narrative on offer is unchanged from the July re-rating: hospital margin expansion compounding through the ACA premium-tax-credit shock rather than after it. Q2 2026 (2026-07-24) delivered consolidated adjusted EBITDA of $1,304M, +16.3% YoY, on revenue of $5,628M (+6.8%), with FY26 adjusted EBITDA guided up $295M at the midpoint to $4,830–5,030M. What has changed since the 2026-08-08 note is not the fundamentals — no company disclosure has landed since the print — but the price and the positioning around it. The last completed daily close was $280.77 on 2026-08-21, a fresh 52-week high, 0.0% off that high, with the shares up 61.6% over three months and RSI(14) at 77.3.

Two things sit awkwardly against that advance. Price is now above the $273.00 average target across brokerages summarised on 2026-08-19, and above every post-print target except UBS/Piper Sandler ($308), Goldman ($305) and the $290 pair (Truist 2026-07-28, Mizuho 2026-08-10). And between 2026-07-27 and 2026-08-06, six insiders filed sales and none filed a purchase. The bid that carried the stock from the 2026-07-24 gap to $280.77 is no longer being fed by fresh estimate revisions.

The narrative is maturing. Dating it — the re-rating headlines are three to four weeks old (nine target raises 2026-07-24→2026-08-03); the only fresh sell-side numbers since are Mizuho's $290 on 2026-08-10 and a Raymond James Outperform reaffirmation at $285 on 2026-08-14; Wall Street Zen cut its tier from strong-buy to buy on 2026-08-15; and coverage has shifted from earnings analysis to retrospective and flow pieces (Benzinga's 15-year total-return retrospective on 2026-08-07, a healthcare options-flow roundup on 2026-08-18). It still works — the tape made a new high on 2026-08-21 — but the incremental information is thinning.

Bullish and bearish views on Tenet Healthcare Corporation New

The model's bull view on Tenet Healthcare Corporation New (THC), in brief: Q2 2026 (2026-07-24): adjusted diluted EPS $6.12 vs $4.02, +52.2%; net income available to common $826M ($9.84 per diluted share). The bear view: Six insider sales, zero purchases, into the advance. Both cases follow in full.

Bull Case

• Q2 2026 (2026-07-24): adjusted diluted EPS $6.12 vs $4.02, +52.2%; net income available to common $826M ($9.84 per diluted share). Operational, not a tax or gain artifact.
• Hospital Operations adjusted EBITDA $762M, +22.3% YoY, 18.0% margin vs 15.6% in Q2 2025, with same-facility admissions +2.3% and adjusted admissions +2.6% — margin gained while exchange volume was falling.
• FY26 guidance raised on every line (2026-07-24): revenue $21,900–22,500M, adjusted EBITDA $4,830–5,030M, adjusted diluted EPS $20.30–21.69, adjusted free cash flow $2,725–3,025M (+$225M midpoint).
• Capital structure: cash $2,170M, net debt/adjusted EBITDA 2.33x, 7.02M shares repurchased year-to-date for $1,360M and an additional $2.0B authorized — a standing bid disclosed in the Q2 release.
• Policy optionality is live and unpriced in guidance. The House passed a three-year extension of the enhanced ACA premium tax credits 230–196 (AHA News, 2026-01-09); the Senate has not advanced it. Guidance embeds roughly a 20% decline in exchange enrollment; a Senate extension would work against that assumption rather than with it.
• The top of the target range is still above the tape: UBS $308 and Piper Sandler $308 (2026-07-27), Goldman Sachs Buy $305 (2026-07-28).

Bear Case

• Six insider sales, zero purchases, into the advance. Form 4 records summarised by SecForm4: Arbour (EVP, CIO) 10,878 sh at $243.90 and Lynch (Director) 3,837 sh at $243.44 and Bierman (Director) 5,000 sh at $244.96, all 2026-07-27; A MarketBeat-derived summary published 2026-08-19 puts three-month insider sales at 41,375 shares for $9,793,347, against insider ownership of 0.97%.
• Price has outrun the consensus it re-rated on. The 2026-08-21 close of $280.77 is above the $273.00 average brokerage target compiled 2026-08-19; five weeks ago the same names were publishing $263–$290.
• Momentum is thinner at a higher price. RSI(14) was 80.9 at the 2026-08-07 close of $262.13 and 77.3 at the 2026-08-21 close of $280.77 — a lower reading against a higher price.
• The 2027 ACA setup is not guided. Management sized the 2026 earnings-growth hit at about $250M with exchange patients converting toward uninsured roughly one-for-one (Healthcare Dive, Becker's, 2026-07-24). Nothing in the Q2 release quantifies 2027.
• USPI is running on price. Ambulatory adjusted EBITDA $542M, +8.8%, 39.0% margin — but same-facility surgical cases were down 1.2% with revenue per case up 6.3%.
• Consolidated EBITDA overstates shareholder economics. USPI's noncontrolling interests take cash before it reaches the buyback; the after-NCI free-cash-flow line is the one that funds the $2.0B authorization.

Setup & Price Structure

• Reference close 2026-08-21: $280.77, equal to the 52-week high; three-month price change +61.6%; RSI(14) 77.3.
• The structure that defines the current leg is the August extension above the prior 52-week high of $262.63 (the 2026-08-07 close was $262.13). That shelf is the first thing a give-back tests, and it is roughly 7% under the last close.
• Beneath it, the 2026-07-24 guidance-raise gap remains unfilled; the stock traded up 17.3% to $233.54 intraday that session with market value quoted at $17.4B. A move back through $233 would be a full round-trip of the raise.
• Crowding observables, stated as observables: price above the compiled average target ($273.00, 2026-08-19); six insider sales and no purchases 2026-07-27→2026-08-06; sell-side revision flow down to one new number in the fifteen sessions before 2026-08-21; general-interest coverage (2026-08-07 long-horizon return retrospective) and an options-flow roundup (2026-08-18) replacing fundamental coverage; Benzinga flagged THC in an overbought-RSI screen on 2026-07-29, when the stock was materially lower than it is now.
• No company-scheduled event stands between now and the Q3 print, estimated ~2026-11-03. The only dated venue inside 30 days is a sector conference at which participation is unconfirmed.

Catalyst Calendar (next 30 days)

• 2026-09-08 to 2026-09-10 — Wells Fargo 21st Annual Healthcare Conference, Boston (dates confirmed via Boston Scientific's 2026-08-10 participation release). Tenet's participation is unconfirmed as of 2026-08-22; management presented at the 2025 edition on 2025-09-03. This is the only plausible venue inside the window for incremental 2027 exchange-attrition framing.
• Outside the window, for calibration: 2026-11-01 ACA open enrollment for plan year 2027 (first hard read on whether the ~20% enrollment decline extends), and ~2026-11-03 (est.) Q3 2026 results with initial 2027 commentary.

Elapsed catalysts

• Unscheduled, any session — Senate action on the House-passed three-year enhanced-premium-tax-credit extension (House vote 230–196, 2026-01-09). No floor date is set as of 2026-08-22; hospital equities have repriced together on this file before. (passed 4d ago)

What Would Change Our Mind

The structure carrying this is the August extension above the prior 52-week high of $262.63 — everything above that level was built in fifteen sessions on no new company disclosure. A weekly close below $262 puts price back inside the post-print range and says the extension was flow, not re-rating; below that, a close through $233 round-trips the 2026-07-24 guidance-raise gap entirely and would say the $295M FY26 EBITDA raise is no longer underwritten.

On the fundamental side, three specific datapoints would break the frame: a 2027 ACA headwind quantified above the ~$250M cited for 2026; same-facility surgical cases printing worse than the -1.2% of Q2 2026 with revenue per case decelerating from +6.3%; or adjusted free cash flow after noncontrolling interests tracking to the low end while net leverage rises above 2.33x. On the flow side, the label moves to saturated if the 2026-09-08–10 conference passes with no Tenet appearance and no new numbers, no further target raises land, and price stalls under $280.77 into a seven-week information vacuum. The opposite case — a Senate vote extending the enhanced credits — would remove the single largest assumption in the bear column and is not in guidance.

Correlation Notes

• Hospital equities trade as one book on premium-tax-credit headlines. The observable to watch is HCA, UHS and THC moving the same direction in the same session with no company-specific news; that pattern, when it appears, is policy beta rather than execution.
• The managed-care complex is the other side of the utilization trade: elevated hospital acuity and admissions (THC same-facility admissions +2.3% in Q2) is the cost line payers guide against, so the two groups can diverge on the same datapoint.
• Ticker-string caution for anyone reading sentiment feeds: social scrapes on "THC" are dominated by cannabis chatter, not Tenet Healthcare. Retail-mention counts on this symbol carry almost no signal about this company.
• The stock's own history is the peer risk: a 61.6% three-month advance in a hospital operator is not a defensive-sector move, and the name has repriced on policy files before with no change in operations.